Supplementary Table 1: Characteristic of patients after propensity-score matching

Factors Immunotherapy

starting in

 0-30 days 31-60 days Total P-value

Total 237 (100%) 237 (100%) 474 (100%)

Institution

 Academic 74 (31%) 67 (28%) 141 (30%) 0.55

 Other 163 (69%) 170 (72%) 333 (70%)

Age

 70 and older 83 (35%) 83 (35%) 166 (35%) 1

 Less than 70 154 (65%) 154 (65%) 308 (65%)

Sex

 Male 125 (53%) 123 (52%) 248 (52%) 0.93

 Female 112 (47%) 114 (48%) 226 (48%)

Race

 White 211 (89%) 212 (89%) 423 (89%) 1

 Other 26 (11%) 25 (11%) 51 (11%)

CD score

* 1. 226 (95%) 226 (95%) 452 (95%) 1

 2-3 11 (5%) 11 (5%) 22 (5%)

Year of diagnosis

 2017 99 (42%) 116 (49%) 215 (45%) 0.14

 2018 138 (58%) 121 (51%) 259 (55%)

Histology

 Adeno 159 (67%) 159 (67%) 318 (67%) 1

 Other 78 (58%) 78 (33%) 156 (33%)

Clinical T stage

 cT3-4 116 (49%) 129 (54%) 245 (52%) 0.27

 Other 121 (51%) 108 (46%) 229 (48%)

Clinical N stage

 cN2-3 155 (65%) 153 (65%) 308 (65%) 0.92

 Other 82 (35%) 84 (35%) 166 (35%)

Clinical M stage

 cM1BC 163 (69%) 162 (68%) 325 (69%) 1

 Other 74 (31%) 75 (32%) 149 (31%)

Surgery

 Yes 2 (1%) 4 (2%) 6 (1%) 0.69

 No 235 (99%) 233 (98%) 468 (99%)

Radiation

 Yes 117 (50%) 116 (49%) 233 (49%) 1

 No 120 (51%) 121 (51%) 241 (51%)

Brain metastasis

 Yes 60 (25%) 52 (22%) 112 (24%) 0.45

 No 177 (75%) 185 (78%) 362 (76%)

Liver metastasis

 Yes 50 (21%) 49 (21%) 99 (21%) 1

 No 187 (79%) 188 (79%) 375 (79%)

CD, Charlson-Deyo; Adeno, adenocarcinoma.